Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases

NCT00716066 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT00716066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00716066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 30, 2008
Completion date
January 31, 2030
Enrollment
53 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune disease, autoimmune nervous system disorder, autologous transplant autoimmune, central nervous system vasculitis, cerebellar degeneration, chronic inflammatory demyelinating polyneuropathy, cidp transplant, hct for neurologic autoimmune disorders, lambert eaton myasthenic syndrome, ms stem cell transplant, multiple sclerosis stem cell transplant, multiple sclerosis transplant, myasthenia gravis, myasthenia gravis transplant, neurologic autoimmune disease, neuromyelitis optica, opsoclonus myoclonus syndrome, rasmussen subacute encephalitis, stiff person syndrome